LRRK2 and Parkinson disease: Patients with genetic PD variants (LRRK2 and GBA) included in another blinded CSF study did not show any differences in RT-QuIC or PMCA outcomes (97.1% concordant sensitivity) compared with patients lacking genetic variants of PD, and these results were concordant with clinical diagnoses [41].